This is supported by a sildenafil-induced reduction in pulmonary arteriolar wall thickness (this study) and by similar beneficial effects of PDE5-inhibitors in experimental models of lung disease, including monocrotaline-induced pulmonary hypertension and bleomycin-induced pulmonary fibrosis [47-49]. Here, PDE5A is linked to pulmonary fibrosis.